Micromet, Inc. (NASDAQ:MITI)

give it a shot

MITI - Offer huge upside in the BioTech sector. I firmly believe this company will get bought out in the next 12-24 months.

I like the research MITI is doing

Market sentiment on selected stocks

While a highly speculative pick, a new anti-cancer drug in Phase II trials appears to be very promising.

From the board chair to the other principals, they are all selling shares like there is no tomorrow. Get out now while the gettin is good!

#1 pick for cure in cancer

see www.micromet.com for info....
explosive potential, also consider buy of AZA, Astra Zeneka who owns Medimmune which is partnering with Micromet.

The BiTE antibody is ingenious and has lots of potential.

Phase 1 Data on MT110 2nd Bite for solid tumors late this year early next!

This company may be on the verge of a possible cure for cancer.

Innovative technology, using antibodies to make the immune system attack cancer cells could be a major breakthrough, plus they have had positive results in clinical trials

their patented safe antibody platform will change the standard in treatment of cancer. they are going to create a royality system of revenues sold throughout the pharma industry. in 10 years , heres another 10 bagger.
Dr. D

4.5 and above is strong resistance in the near term.

MITI has a too high valuation compared to its sales potential. It is also one of the most loss making companies.

- Forecasted Earnings per Share of $-0.73 per share
- P/E of of -4.82
- Earnings Yield of -20.74 percent
- Growth to P/E Ratio of -0.20

bad company ready to go down

Listen carefully: This stock will be at $20 on or around December 6th-9th. These dates are the 50th ASH meeting where MITI will present phae II data from its drug MT203. If results are positive, the stock will soar. So far, results have been close to 100% positive. December will be the time of the catalyst. Get in before its too late. Good Luck

The worst company on earth.